FINWIRES · TerminalLIVE
FINWIRES

$GEHC

33 stories mentioning GEHCUpdated just now

Every FINWIRES story that references GEHC, newest first.

Wire

GE HealthCare's Continued Underperformance in Patient Care Solutions Business 'Disappointing,' Oppenheimer Says

GE HealthCare Technologies' (GEHC) continued underperformance in the Patient Care Solutions business is "disappointing," with the segment experiencing fulfillment challenges in Q2, Oppenheimer said in a Thursday note.The company is exploring a strategic review for PCS, which includes either continued ownership, sale, or other value enhancing transactions, Oppenheimer said, adding that the timeline of the review remains unclear, with GE HealthCare looking to stabilize the business first.Additionally, the company reiterated organic revenue growth at 3% to 4%, as well as adjusted earnings per share $4.80 to $5.00, compared with Oppenheimer estimate of $4.90, according to the note.Oppenheimer said it remains constructive long-term given the company's ecosystem and multiple growth levers, although China, tariffs, and other macro pressures remain as overhangs.Oppenheimer maintained its outperform rating with a price target of $85 on GE HealthCare.Price: $69.04, Change: $-2.86, Percent Change: -3.98%

$GEHC
Wire

Evercore ISI Adjusts GE Healthcare Technologies Price Target to $84 From $80

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $78.82, according to analysts polled by FactSet.Price: $70.47, Change: $+6.36, Percent Change: +9.92%

$GEHC
Sectors

Sector Update: Health Care Stocks Higher Pre-Bell Wednesday

Healthcare stocks were higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.3% and the iShares Biotechnology ETF (IBB) advancing 0.5%.Humana (HUM) stock was down more than 2% premarket after the company cut its 2026 GAAP earnings guidance.GE Healthcare Technologies (GEHC) shares were 9% higher after the company reported higher Q2 adjusted earnings and revenue.Fortrea (FTRE) gained more than 3% after the company reported higher-than-expected Q2 adjusted earnings and revenue.

$FTRE$GEHC$HUM$IBB$XLV
Stocks Mostly Up Pre-Bell Ahead of Fed Rate Decision, Big Tech Earnings
US Markets

Stocks Mostly Up Pre-Bell Ahead of Fed Rate Decision, Big Tech Earnings

The main US stock measures were mostly trending higher in Wednesday's premarket activity as traders await a major policy decision by the Federal Reserve and the latest quarterly results of two of the largest technology companies.The S&P 500 rose 0.2% and the Dow Jones Industrial Average edged up 0.1% before the opening bell, while the Nasdaq declined 0.1%. The S&P 500 and the Dow finished Tuesday trading in the green, with the latter recording its third consecutive day of gains, while the Nasdaq closed lower for the fifth straight session.The Fed's monetary policy committee will announce its latest decision on interest rates at 2 pm ET. The probability of the central bank leaving its benchmark lending rate unchanged stood at about 66% on Wednesday, with the remaining odds in favor of a quarter-percentage-point increase, according to the CME FedWatch tool.Fed Chair Kevin Warsh is expected to hold a press conference at 2:30 pm."The doves are optimistic that inflation could cool further into year-end as the impact of tariffs rolls off and energy prices stabilize," Stifel said in a report Tuesday. "The recent rise in tensions overseas, however, coupled with (artificial intelligence)-sector price pressures suggest further upside inflationary risks remain, shifting the pendulum back into the hawk's camp."Treasury yields were up in premarket action, with the two-year rate increasing 2.9 basis points to 4.31% and the 10-year rate adding 1.6 basis points to 4.62%.Iran's Islamic Revolutionary Guard Corps launched multiple ballistic missiles in "an attempted surprise attack" on US forces based in the Middle East, the US Central Command said in a Tuesday post on the X platform. "All Iranian missiles were successfully intercepted," according to CENTCOM.In a separate statement, CENTCOM said it launched joint strikes with the Saudi Arabian armed forces against "Iran-aligned terrorists" in Iraq on Tuesday.West Texas Intermediate crude oil inclined 3.7% to $82.03 a barrel before the open, while Brent advanced 3.7% to $87.16.Microsoft (MSFT) and Meta Platforms (META) are scheduled to release their latest financial results after the markets close, along with Arm Holdings (ARM), Qualcomm (QCOM) and Starbucks (SBUX).Procter & Gamble (PG), Amphenol (APH), General Dynamics (GD), Johnson Controls (JCI), Boston Scientific (BSX), Humana (HUM) and GE HealthCare Technologies (GEHC) post their earnings before the bell, among others.Shares of Visa (V) decreased 0.8% pre-bell after the payments company reported its fiscal third-quarter results. Ford Motor (F) gained 4.3% as the automaker lifted its full-year core profit outlook. Lucid Group (LCID) was down 0.8% following a 21% jump at the close of Tuesday as Saudi Prince Alwaleed Bin Talal Al Saud disclosed a 5% stake in the company.Wednesday's economic calendar also has the weekly mortgage applications bulletin at 7 am, followed by the EIA domestic petroleum inventories report at 10:30 am.Gold slipped 0.2% to $4,032 per troy ounce, while bitcoin rose 1.4% to $64,588.

Dow JonesNasdaq CompositeS&P 500$APH$ARM$BSX$F$GD$GEHC$HUM$JCI$LCID$META$MSFT$PG$QCOM$SBUX$V
Wire

GE Healthcare Q2 Prelim Likely to Ease Overhang, RBC Says

GE Healthcare Technologies' (GEHC) preliminary Q2 report should ease investor worries over cost inflation and other issues, RBC Capital Markets said in a Thursday note.The firm pre-released Q2 results with organic revenue above consensus and a material EPS upside surprise, the report said. GE also said CFO James Saccaro will step down from his role.The note said it was a "positive" event for the stock amid cautious investor sentiment heading into Q2 over cost inflation, tariff headwinds, and hospital capital spending uncertainty."We believe the constructive tone (strong orders, healthy end market demand)...paired with 2026 guide reaffirmation should help alleviate some near-term overhang and the CFO transition," the report said.RBC maintained its outperform rating and a $80 price target.Price: $61.35, Change: $-0.64, Percent Change: -1.03%

$GEHC
Wire

GE Healthcare's Flyrcado Adoption Faces Headwinds, UBS Says

GE Healthcare Technologies (GEHC) expects Flyrcado imaging agent sales of $500 million by 2028, but a slower-than-expected launch has weakened buy-side confidence in the product, UBS Securities said.The adoption of the Flyrcado tracer, used to diagnose coronary artery disease, is being limited by radiopharmacy investment requirements, hospital switching costs and uncertainty over future reimbursement, analysts wrote in a Wednesday research report.The investment firm said the shares are reasonably priced but expects the challenges around Flyrcado to slow adoption and leave its earnings estimates below consensus from 2027 onward.UBS reiterated its neutral rating on the stock and cut its price target to $67 per share from $69.Shares of GE Healthcare were up 1.5% in Thursday afternoon trading.Price: $64.17, Change: $+0.97, Percent Change: +1.53%

$GEHC
Wire

GE Healthcare Technologies Keeps Quarterly Dividend at $0.035 a Share, Payable Aug. 14 to Holders of Record July 24

GE Healthcare Technologies Keeps Quarterly Dividend at $0.035 a Share, Payable Aug. 14 to Holders of Record July 24

$GEHC
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 1.5% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.3%.The iShares Biotechnology ETF (IBB) advanced 0.7%.In sector news, the US Justice Department is expected to charge about 450 defendants in alleged healthcare fraud schemes worth more than $6.5 billion, marking its largest coordinated antifraud operation to date, The Wall Street Journal reported, citing federal officials.In corporate news, AbbVie (ABBV) shares gained 1.8% after it said Tuesday that the European Commission approved its therapy Maviret to treat acute hepatitis C virus infection in adults and children aged three years and older.Merck (MRK) shares rose 3.1%. The company said Monday its investigational antibody tulisokibart met primary and secondary endpoints in a phase 3 trial of people with moderately to severely active ulcerative colitis.GE HealthCare Technologies (GEHC) is positioned for accelerating growth, driven by improving innovation, order momentum, and backlog, RBC Capital Markets said in a note. RBC started coverage of the company with an outperform rating and an $80 price target. GE HealthCare shares climbed 4.8%.Boundless Bio (BOLD) shares surged 80% after the company said it signed a definitive merger agreement with privately held biotech firm Serapha Bio.

$ABBV$BOLD$GEHC$MRK
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) advanced 1.5%.In sector news, the US Justice Department is expected to charge about 450 defendants in alleged healthcare fraud schemes worth more than $6.5 billion, marking its largest coordinated antifraud operation to date, The Wall Street Journal reported, citing federal officials.In corporate news, GE HealthCare Technologies (GEHC) is positioned for accelerating growth, driven by improving innovation, order momentum, and backlog, RBC Capital Markets said in a note. RBC started coverage of the company with an outperform rating and an $80 price target. GE HealthCare shares climbed 4.6%.Eli Lilly (LLY) and Astellas Pharma have entered into two separate asset sale agreements with Sangamo Therapeutics as part of Sangamo's voluntary Chapter 11 reorganization, the genomic medicine company said Tuesday. Lilly shares added 0.4%.Boundless Bio (BOLD) shares surged 85% after the company said it signed a definitive merger agreement with privately held biotech firm Serapha Bio.

$BOLD$GEHC$LLY
Sectors

Sector Update: Healthcare

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.3%.The iShares Biotechnology ETF (IBB) advanced 1.5%.In corporate news, GE HealthCare Technologies (GEHC) is positioned for accelerating growth, driven by improving innovation, order momentum, and backlog, RBC Capital Markets said in a note. RBC started coverage of the company with an outperform rating and an $80 price target. GE HealthCare shares climbed 4.9%.

$GEHC
Wire

GE HealthCare Technologies Set for Further Growth on Strong Backlog, Execution, RBC Says

GE HealthCare Technologies (GEHC) is positioned for accelerating growth, driven by improving innovation, order momentum, and backlog, RBC Capital Markets said in a note Monday.The analysts said they have a positive outlook on the company as GE HealthCare Technologies offers an attractive risk-reward profile, with its valuation not fully reflecting its growth potential.Following its 2023 separation from General Electric, the company has increased research and development investment and improved commercial execution, helping to drive 5% year-over-year order growth in 2025.The company also has a strong $22 billion backlog, roughly equivalent to its expected 2026 revenue, positioning it for faster growth later in the year toward its long-range plan.Management is targeting annual organic revenue growth of 4% to 6% between 2026 and 2028, along with high-single-digit to low-double-digit earnings-per-share growth, the analysts said.For sales, GE HealthCare is expected to deliver organic revenue growth within its 3% to 4% guidance range in 2026, the analysts said, adding that they expect 2027 EPS of $5.45, slightly above the consensus estimate of $5.40.RBC initiated coverage of GE HealthCare Technologies with an outperform rating and an $80 price target.Price: $62.47, Change: $+1.83, Percent Change: +3.02%

$GEHC
Research

RBC Initiates GE Healthcare Technologies at Outperform With $80 Price Target

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $78.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$GEHC
Research

UBS Upgrades GE Healthcare Technologies to Neutral From Sell, Adjusts Price Target to $69 From $75

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $78.59, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$GEHC
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.

$GEHC
Wire

BNP Paribas Adjusts GE Healthcare Technologies Price Target to $88 From $95

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.61, Change: $-0.23, Percent Change: -0.38%

$GEHC
Wire

Rothschild & Co Redburn Adjusts Price Target on GE Healthcare Technologies to $98 From $110

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $60.02, Change: $+0.53, Percent Change: +0.89%

$GEHC
Wire

Barclays Adjusts Price Target on GE Healthcare Technologies to $78 From $87

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $60.02, Change: $+0.53, Percent Change: +0.89%

$GEHC
Wire

Citigroup Adjusts Price Target on GE Healthcare Technologies to $65 From $80

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $60.03, Change: $+0.55, Percent Change: +0.92%

$GEHC
Wire

Mizuho Adjusts Price Target on GE Healthcare Technologies to $80 From $90

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $60.04, Change: $+0.55, Percent Change: +0.92%

$GEHC
Wire

Jefferies Adjusts Price Target on GE Healthcare Technologies to $90 From $105

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $60.04, Change: $+0.56, Percent Change: +0.93%

$GEHC

Showing 1-20 of 33

Track with the FINWIRES app suite